CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is...
Phase 1
Houston, Texas, United States and 18 other locations
The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control CLL. The safety of this dru...
Phase 2
Houston, Texas, United States
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Houston, Texas, United States and 21 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Houston, Texas, United States and 73 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Houston, Texas, United States and 130 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Kingwood, Texas, United States and 216 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Houston, Texas, United States and 83 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Houston, Texas, United States and 179 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Houston, Texas, United States and 79 other locations
as:* Monotherapy, or* Combination therapy for relapsed/refractory chronic lymphocytic leukemia (R/R CLL): * epcoritamab +...
Phase 1, Phase 2
Houston, Texas, United States and 76 other locations
Clinical trials
Research sites
Resources
Legal